ACADIA Pharmaceuticals Inc. (ACAD) is a Biotechnology company in the Healthcare sector, currently trading at $22.02. It has a SharesGrow Score of 85/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ACAD = $24.35 (+10.6% from the current price, the stock appears fairly valued). Analyst consensus target is ACAD = $35 (+57.9% upside).
Valuation: ACAD trades at a trailing Price-to-Earnings (P/E) of 9.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $1.1B, +28.1%/yr average growth. Net income is $391M, growing at +204.6%/yr. Net profit margin is 36.5% (strong). Gross margin is 91.7% (-6.3 pp trend).
Balance sheet: total debt is $52M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 3.83 (strong liquidity). Debt-to-assets is 3.3%. Total assets: $1.6B.
Analyst outlook: 26 / 37 analysts rate ACAD as buy (70%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 59/100 (Partial), Future 85/100 (Pass), Income 100/100 (Pass).
